1
|
Siegel R, Desantis C and Jemal A:
Colorectal cancer statistics, 2014. CA Cancer J Clin. 64:104–117.
2014. View Article : Google Scholar : PubMed/NCBI
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
3
|
Andrews L: Dietary flavonoids for the
prevention of colorectal cancer. Clin J Oncol Nurs. 17:671–672.
2013. View Article : Google Scholar : PubMed/NCBI
|
4
|
Altobelli E, Lattanzi A, Paduano R,
Varassi G and di Orio F: Colorectal cancer prevention in Europe:
Burden of disease and status of screening programs. Prev Med.
62:132–141. 2014. View Article : Google Scholar : PubMed/NCBI
|
5
|
Sugarbaker PH: Colorectal cancer:
Prevention and management of metastatic disease. Biomed Res Int.
2014:7828902014. View Article : Google Scholar : PubMed/NCBI
|
6
|
Chan DS, Lau R, Aune D, Vieira R,
Greenwood DC, Kampman E and Norat T: Red and processed meat and
colorectal cancer incidence: Meta-analysis of prospective studies.
PLoS One. 6:e204562011. View Article : Google Scholar : PubMed/NCBI
|
7
|
Zhu M, Xu Y, Ge M, Gui Z and Yan F:
Regulation of UHRF1 by microRNA-9 modulates colorectal cancer cell
proliferation and apoptosis. Cancer Sci. 106:833–839. 2015.
View Article : Google Scholar : PubMed/NCBI
|
8
|
Gupta GP and Massague J: Cancer
metastasis: Building a framework. Cell. 127:679–695. 2006.
View Article : Google Scholar : PubMed/NCBI
|
9
|
Spano D, Heck C, De Antonellis P,
Christofori G and Zollo M: Molecular networks that regulate cancer
metastasis. Semin Cancer Biol. 22:234–249. 2012. View Article : Google Scholar : PubMed/NCBI
|
10
|
Xiong Y, Zhang YY, Wu YY, Wang XD, Wan LH,
Li L and Zhou LM: Correlation of over-expressions of miR-21 and
Notch-1 in human colorectal cancer with clinical stages. Life Sci.
106:19–24. 2014. View Article : Google Scholar : PubMed/NCBI
|
11
|
Manfredi S, Bouvier AM, Lepage C, Hatem C,
Dancourt V and Faivre J: Incidence and patterns of recurrence after
resection for cure of colonic cancer in a well defined population.
Br J Surg. 93:1115–1122. 2006. View
Article : Google Scholar : PubMed/NCBI
|
12
|
Van Cutsem E, Cervantes A, Nordlinger B
and Arnold D; ESMO Guidelines Working Group, : Metastatic
colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis,
treatment and follow-up. Ann Oncol. 25 Suppl 3:iii1–9. 2014.
View Article : Google Scholar : PubMed/NCBI
|
13
|
Yuan W, Sui C, Liu Q, Tang W, An H and Ma
J: Up-regulation of microRNA-145 associates with lymph node
metastasis in colorectal cancer. PLoS One. 9:e1020172014.
View Article : Google Scholar : PubMed/NCBI
|
14
|
Liu L, Chen L, Xu Y, Li R and Du X:
microRNA-195 promotes apoptosis and suppresses tumorigenicity of
human colorectal cancer cells. Biochem Biophys Res Commun.
400:236–240. 2010. View Article : Google Scholar : PubMed/NCBI
|
15
|
Chen DL, Wang ZQ, Zeng ZL, Wu WJ, Zhang
DS, Luo HY, Wang F, Qiu MZ, Wang DS, Ren C, et al: Identification
of microRNA-214 as a negative regulator of colorectal cancer liver
metastasis by way of regulation of fibroblast growth factor
receptor 1 expression. Hepatology. 60:598–609. 2014. View Article : Google Scholar : PubMed/NCBI
|
16
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
17
|
O'Hara SP, Mott JL, Splinter PL, Gores GJ
and LaRusso NF: MicroRNAs: key modulators of posttranscriptional
gene expression. Gastroenterology. 136:17–25. 2009. View Article : Google Scholar : PubMed/NCBI
|
18
|
Croce CM and Calin GA: miRNAs, cancer and
stem cell division. Cell. 122:6–7. 2005. View Article : Google Scholar : PubMed/NCBI
|
19
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
20
|
Martens-Uzunova ES, Olvedy M and Jenster
G: Beyond microRNA-novel RNAs derived from small non-coding RNA and
their implication in cancer. Cancer Lett. 340:201–211. 2013.
View Article : Google Scholar : PubMed/NCBI
|
21
|
Yu X, Zhang X, Dhakal IB, Beggs M,
Kadlubar S and Luo D: Induction of cell proliferation and survival
genes by estradiol-repressed microRNAs in breast cancer cells. BMC
Cancer. 12:292012. View Article : Google Scholar : PubMed/NCBI
|
22
|
Yanokura M, Banno K, Kobayashi Y, Kisu I,
Ueki A, Ono A, Masuda K, Nomura H, Hirasawa A, Susumu N and Aoki D:
MicroRNA and endometrial cancer: Roles of small RNAs in human
tumors and clinical applications (Review). Oncol Lett. 1:935–940.
2010.PubMed/NCBI
|
23
|
Ventura A and Jacks T: MicroRNAs and
cancer: Short RNAs go a long way. Cell. 136:586–591. 2009.
View Article : Google Scholar : PubMed/NCBI
|
24
|
Yang T, Thakur A, Chen T, Yang L, Lei G,
Liang Y, Zhang S, Ren H and Chen M: MicroRNA-15a induces cell
apoptosis and inhibits metastasis by targeting BCL2L2 in non-small
cell lung cancer. Tumour Biol. 36:4357–4365. 2015. View Article : Google Scholar : PubMed/NCBI
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
26
|
Gao B, Gao K, Li L, Huang Z and Lin L:
miR-184 functions as an oncogenic regulator in hepatocellular
carcinoma (HCC). Biomed Pharmacother. 68:143–148. 2014. View Article : Google Scholar : PubMed/NCBI
|
27
|
Wong TS, Liu XB, Wong BY, Ng RW, Yuen AP
and Wei WI: Mature miR-184 as potential oncogenic microRNA of
squamous cell carcinoma of tongue. Clin Cancer Res. 14:2588–2592.
2008. View Article : Google Scholar : PubMed/NCBI
|
28
|
Su Z, Chen D, Li Y, Zhang E, Yu Z, Chen T,
Jiang Z, Ni L, Yang S, Gui Y, et al: microRNA-184 functions as
tumor suppressor in renal cell carcinoma. Exp Ther Med. 9:961–966.
2015.PubMed/NCBI
|
29
|
Zhen Y, Liu Z, Yang H, Yu X, Wu Q, Hua S,
Long X, Jiang Q, Song Y, Cheng C, et al: Tumor suppressor PDCD4
modulates miR-184-mediated direct suppression of C-MYC and BCL2
blocking cell growth and survival in nasopharyngeal carcinoma. Cell
Death Dis. 4:e8722013. View Article : Google Scholar : PubMed/NCBI
|
30
|
Tivnan A, Foley NH, Tracey L, Davidoff AM
and Stallings RL: MicroRNA-184-mediated inhibition of tumour growth
in an orthotopic murine model of neuroblastoma. Anticancer Res.
30:4391–4395. 2010.PubMed/NCBI
|
31
|
Lin TC, Lin PL, Cheng YW, Wu TC, Chou MC,
Chen CY and Lee H: MicroRNA-184 deregulated by the microRNA-21
promotes tumor malignancy and poor outcomes in non-small cell lung
cancer via targeting CDC25A and c-Myc. Ann Surg Oncol. 22 Suppl
3:S1532–S1539. 2015. View Article : Google Scholar : PubMed/NCBI
|
32
|
Feng R and Dong L: Inhibitory effect of
miR-184 on the potential of proliferation and invasion in human
glioma and breast cancer cells in vitro. Int J Clin Exp Pathol.
8:9376–9382. 2015.PubMed/NCBI
|
33
|
Cheng Z, Wang HZ, Li X, Wu Z, Han Y, Li Y,
Chen G, Xie X, Huang Y, Du Z, et al: MicroRNA-184 inhibits cell
proliferation and invasion and specifically targets TNFAIP2 in
Glioma. J Exp Clin Cancer Res. 34:272015. View Article : Google Scholar : PubMed/NCBI
|
34
|
Wong TS, Ho WK, Chan JY, Ng RW and Wei WI:
Mature miR-184 and squamous cell carcinoma of the tongue.
Scientific World Journal. 9:130–132. 2009. View Article : Google Scholar : PubMed/NCBI
|
35
|
Wu GG, Li WH, He WG, Jiang N, Zhang GX,
Chen W, Yang HF, Liu QL, Huang YN, Zhang L, et al: Mir-184
post-transcriptionally regulates SOX7 expression and promotes cell
proliferation in human hepatocellular carcinoma. PLoS One.
9:e887962014. View Article : Google Scholar : PubMed/NCBI
|
36
|
Yu Z, Ni L, Chen D, Zhang Q, Su Z, Wang Y,
Yu W, Wu X, Ye J, Yang S, et al: Identification of miR-7 as an
oncogene in renal cell carcinoma. J Mol Histol. 44:669–677. 2013.
View Article : Google Scholar : PubMed/NCBI
|
37
|
Hu Q, Gong JP, Li J, Zhong SL, Chen WX,
Zhang JY, Ma TF, Ji H, Lv MM, Zhao JH and Tang JH: Down-regulation
of miRNA-452 is associated with adriamycin-resistance in breast
cancer cells. Asian Pac J Cancer Prev. 15:5137–5142. 2014.
View Article : Google Scholar : PubMed/NCBI
|
38
|
Wang YH, Wang ZX, Qiu Y, Xiong J, Chen YX,
Miao DS and De W: Lentivirus-mediated RNAi knockdown of
insulin-like growth factor-1 receptor inhibits growth, reduces
invasion and enhances radiosensitivity in human osteosarcoma cells.
Mol Cell Biochem. 327:257–266. 2009. View Article : Google Scholar : PubMed/NCBI
|
39
|
Wang YH, Han XD, Qiu Y, Xiong J, Yu Y,
Wang B, Zhu ZZ, Qian BP, Chen YX, Wang SF, et al: Increased
expression of insulin-like growth factor-1 receptor is correlated
with tumor metastasis and prognosis in patients with osteosarcoma.
J Surg Oncol. 105:235–243. 2012. View Article : Google Scholar : PubMed/NCBI
|
40
|
Scharf JG and Braulke T: The role of the
IGF axis in hepatocarcinogenesis. Horm Metab Res. 35:685–693. 2003.
View Article : Google Scholar : PubMed/NCBI
|
41
|
Shiratsuchi I, Akagi Y, Kawahara A,
Kinugasa T, Romeo K, Yoshida T, Ryu Y, Gotanda Y, Kage M and
Shirouzu K: Expression of IGF-1 and IGF-1R and their relation to
clinicopathological factors in colorectal cancer. Anticancer Res.
31:2541–2545. 2011.PubMed/NCBI
|
42
|
Werner H and LeRoith D: The role of the
insulin-like growth factor system in human cancer. Adv Cancer Res.
68:183–223. 1996. View Article : Google Scholar : PubMed/NCBI
|
43
|
Pollak M: The insulin and insulin-like
growth factor receptor family in neoplasia: An update. Nat Rev
Cancer. 12:159–169. 2012.PubMed/NCBI
|
44
|
King H, Aleksic T, Haluska P and Macaulay
VM: Can we unlock the potential of IGF-1R inhibition in cancer
therapy? Cancer Treat Rev. 40:1096–1105. 2014. View Article : Google Scholar : PubMed/NCBI
|
45
|
Hewish M, Chau I and Cunningham D:
Insulin-like growth factor 1 receptor targeted therapeutics: Novel
compounds and novel treatment strategies for cancer medicine.
Recent Pat Anticancer Drug Discov. 4:54–72. 2009. View Article : Google Scholar : PubMed/NCBI
|
46
|
Wu J and Zhu AX: Targeting insulin-like
growth factor axis in hepatocellular carcinoma. J Hematol Oncol.
4:302011. View Article : Google Scholar : PubMed/NCBI
|